Drug
Placebo (human albumin 1%)
Placebo (human albumin 1%) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Recruiting1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
recruiting133%
completed133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938
terminatedphase_3
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
NCT05531149
completedphase_2
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
NCT04576728
Clinical Trials (3)
Showing 3 of 3 trials
NCT05722938Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05531149Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
NCT04576728Phase 2
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3